Standard treatment for resectable endometrial cancer often consists of surgery ... Prior studies showed immune checkpoint blockade in the neoadjuvant setting conferred favorable outcomes for ...
6d
The therapy, a fully human monoclonal antibody, targets a newly identified immune checkpoint protein that could enhance ...
SPP1+ Macrophages Identified as Key Drivers and Therapeutic Targets In Colorectal Cancer Progression
Colorectal cancer (CRC) is the third most common malignancy and the second leading cause of cancer-related deaths worldwide.
While PD-1/PD-L1 blockade has demonstrated remarkable clinical successes, recent studies suggest that its novel target has a ...
The therapy, a fully human monoclonal antibody, targets a newly identified immune checkpoint protein that could enhance ...
Karnataka: Shilpa Biologicals Pvt Ltd., a fully owned subsidiary of Shilpa Medicare Limited has signed an exclusive ...
Hepatocellular carcinoma (HCC), the third leading cause of cancer-related deaths worldwide, remains one of the most ...
The novel therapy is anticipated to function like PD-1/PD-L1 blockade with significant clinical efficacy results in ...
AbTree Biologics AG has signed an exclusive co-development and commercialization partnership with Shilpa Biologicals Pvt Ltd.
Interim analysis of overall survival in potentially registrational phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer expected in late ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback